Revelation Capital Management, LLC has filed a Form 13F-HR with the Securities and Exchange Commission, disclosing its equity securities portfolio as of the close of business on September 30, 2026. The filing, signed by Managing Partner Michael Boggs on November 2, 2026, lists the firm's total holdings as 2,933,111 shares.
The portfolio consists of two distinct positions. The largest holding is in Artiva Biotherapeutics Inc., where Revelation Capital holds 2,993,111 shares. The second position is in Obsidian Therapeutics Inc., where the firm holds 428,346 shares. Both positions are reported as sole voting and sole dispositive power.
